I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Capital Investment Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 12.1% during ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...